Therapeutic area intelligence for IL-6 Inhibitor with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Biogen →

Assets

FDA →

TYENNE →

Recent signals(3)

RegulatoryJuly 20, 2026

FDA Accepts Supplement Application for TOFIDENCE (Tocilizumab-Bavi)

The FDA has accepted the supplemental application for BLA761354, which includes Tocilizumab-Bavi as an active ingredient.

RegulatoryJuly 20, 2026

FDA Approves Supplemental Application for TYENNE (Tocilizumab-AAZG)

The FDA has approved a supplemental application for TYENNE, a formulation of Tocilizumab-AAZG, submitted by Fresenius Kabi USA.

RegulatoryJuly 19, 2026

FDA Approves Supplement for TYENNE (Tocilizumab-AAZG) by Fresenius Kabi

The FDA has approved a supplemental application for TYENNE, a formulation of Tocilizumab-AAZG.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.